VX-770 Expanded Access Program
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01381289|
Expanded Access Status : Approved for marketing
First Posted : June 27, 2011
Last Update Posted : February 9, 2012
|Condition or disease||Intervention/treatment|
|Cystic Fibrosis||Drug: VX-770|
VX-770, a compound being developed by Vertex Pharmaceuticals Incorporated (Vertex) for the treatment of CF, is an orally bioavailable small molecule that targets the underlying defect in CF, the dysfunctional CFTR protein. In Phase 3 studies of VX-770 in patients with CF and a G551D CFTR mutation, improvements in CFTR function (measured by reduction in sweat chloride concentration) and improvements in lung function were observed.
Patients who are interested in the VX-770 Expanded Access should contact their CF physician about participation.
Physicians interested in participating as a site should contact 800-745-4484.
|Study Type :||Expanded Access|
|Official Title:||VX-770 Expanded Access Program (EAP)|
- Drug: VX-770
150 mg tablet, oral use, twice daily every 12 hours (q12h)